A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib
Although some success has been achieved in identifying Epidermal growth factor receptor
(EGFR) mutations as a molecular predictive marker of response in patients with non-small
cell lung cancer (NSCLC), this strategy is likely only to be limited as not all responding
patients have a mutation in their tumor and conversely, not all patients with a mutation
were responders. Furthermore, as the development of resistance to EGFR tyrosine kinase
inhibitors (TKI) such as gefitinib, erlotinib is inevitable and poses a major clinical
problem due to limited therapeutic options, the identification of a molecular profile that
could predict sensitivity to erlotinib or gefitinib is warranted.
Using serum as an easily accessible biological fluid, we hypothesize that EGFR TKIs modulate
tumor changes that may be reflected in the alteration of serum proteins.
- To establish the serum proteomic changes in NSCLC patients receiving erlotinib or
- To identify a serum protein profile that predicts erlotinib or gefitinib sensitivity or
resistance in NSCLC patients with and without EGFR mutations.
- To study the toxicity of erlotinib or gefitinib by correlating clinical toxicity with
serum protein profile.
An extensive profiling of the molecular circuitry affected by EGFR TKIs would be helpful in
understanding the response and side effects of patients with NSCLC treated with erlotinib or
gefitinib and could guide therapy and thus improve patient outcome.
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Ross Andrew Soo, MBBS
National University Hospital, Singapore
Singapore: Domain Specific Review Boards